Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nolasiban dosing regimens for uterine contractility in women undergoing IVF/ICSI preparation
2025-524896-22-00Phase 2Authorised
- Sponsor
- ReproNovo
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nolasiban in female infertility (3 arms), sponsored by ReproNovo. Primary endpoint: Change in uterine contractility index from Day 1 to Day 4 of treatment. Planned start May 2026; status: authorised.
02
Drugs
nolasiban
03
Conditions
female infertility
Beyond the preview
Go deeper on 2025-524896-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524896-22-00.